NETO2 promotes melanoma progression via activation of the Ca^(2+)/CaMKⅡ signaling pathway  

作　　者：Susi Zhu Xu Zhang Yeye Guo Ling Tang Zhe Zhou Xiang Chen Cong Peng 

机构地区：[1]Department of Dermatology,Xiangya Hospital,Central South University,Changsha 41000,China [2]Hunan Key Laboratory of Skin Cancer and Psoriasis,Changsha 41000,China [3]Hunan Engineering Research Center of Skin Health and Disease,Changsha 41000,China [4]National Clinical Research Center for Geriatric Disorders,Xiangya Hospital,Central South University,Changsha 41000,China [5]Department of Clinical Pharmacology,Xiangya Hospital,Central South University,Changsha 41000,China

出　　处：《Frontiers of Medicine》2023年第2期263-274,共12页医学前沿（英文版）

基　　金：supported by the National Natural Science Foundation of China(Nos.82073458,82173424,81773341,81772917,and 81830096);supported by the Science and Technology Innovation Program of Hunan Province(No.2021RC4013);the Program of Introducing Talents of Discipline to Universities(111 Project,No.B20017)。

摘　　要：Melanoma is the most aggressive cutaneous tumor.Neuropilin and tolloid-like 2(NETO2)is closely related to tumorigenesis.However,the functional significance of NETO2 in melanoma progression remains unclear.Herein,we found that NETO2 expression was augmented in melanoma clinical tissues and associated with poor prognosis in melanoma patients.Disrupting NETO2 expression markedly inhibited melanoma proliferation,malignant growth,migration,and invasion by downregulating the levels of calcium ions(Ca^(2+))and the expression of key genes involved in the calcium signaling pathway.By contrast,NETO2 overexpression had the opposite effects.Importantly,pharmacological inhibition of CaMKII/CREB activity with the CaMKII inhibitor KN93 suppressed NETO2-induced proliferation and melanoma metastasis.Overall,this study uncovered the crucial role of NETO2-mediated regulation in melanoma progression,indicating that targeting NETO2 may effectively improve melanoma treatment.

关 键 词：MELANOMA neuropilin and tolloid-like 2 CA^(2+) CaMKII signaling pathway 

分 类 号：R739.5[医药卫生—肿瘤]